Hellman Jordan Management Co. Inc. MA Buys New Stake in Celgene Corporation (CELG)

Hellman Jordan Management Co. Inc. MA bought a new position in shares of Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 74,979 shares of the biopharmaceutical company’s stock, valued at approximately $9,737,000. Celgene Corporation comprises about 20.9% of Hellman Jordan Management Co. Inc. MA’s investment portfolio, making the stock its largest holding.

A number of other large investors also recently added to or reduced their stakes in the business. Neuberger Berman Group LLC boosted its holdings in shares of Celgene Corporation by 4.0% in the 1st quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after acquiring an additional 71,729 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Celgene Corporation by 27.2% in the 1st quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock valued at $341,796,000 after acquiring an additional 588,000 shares during the last quarter. Boston Partners boosted its holdings in shares of Celgene Corporation by 0.3% in the 1st quarter. Boston Partners now owns 197,861 shares of the biopharmaceutical company’s stock valued at $24,620,000 after acquiring an additional 541 shares during the last quarter. Chicago Equity Partners LLC boosted its holdings in shares of Celgene Corporation by 148.8% in the 1st quarter. Chicago Equity Partners LLC now owns 86,480 shares of the biopharmaceutical company’s stock valued at $10,761,000 after acquiring an additional 51,715 shares during the last quarter. Finally, Train Babcock Advisors LLC purchased a new stake in shares of Celgene Corporation in the 1st quarter valued at $205,000. 79.43% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://ledgergazette.com/2017/09/17/hellman-jordan-management-co-inc-ma-buys-new-stake-in-celgene-corporation-celg.html.

In other news, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the completion of the transaction, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gilla Kaplan sold 9,250 shares of Celgene Corporation stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Insiders have sold a total of 267,476 shares of company stock valued at $35,812,841 in the last ninety days. Corporate insiders own 0.95% of the company’s stock.

Several analysts have recently commented on the stock. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $175.00 price objective on shares of Celgene Corporation in a report on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $160.00 price objective on shares of Celgene Corporation in a report on Friday. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective on the stock in a report on Wednesday, August 16th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Celgene Corporation in a report on Friday, July 14th. Finally, Bank of America Corporation reaffirmed a “buy” rating on shares of Celgene Corporation in a report on Wednesday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $149.34.

Shares of Celgene Corporation (CELG) traded up 1.02% during midday trading on Friday, hitting $142.04. 5,983,997 shares of the stock were exchanged. The firm has a market cap of $111.12 billion, a PE ratio of 43.99 and a beta of 1.89. The firm has a 50-day moving average price of $134.97 and a 200 day moving average price of $127.46. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $142.69.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business’s revenue was up 18.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.44 EPS. Analysts predict that Celgene Corporation will post $7.33 earnings per share for the current fiscal year.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply